UCB SA (EBR:UCB)
Belgium · Delayed Price · Currency is EUR | Market Cap | 51.59B +67.6% |
| Revenue (ttm) | 7.74B +25.8% |
| Net Income | 1.56B +46.3% |
| EPS | 8.03 +46.5% |
| Shares Out | 190.36M |
| PE Ratio | 33.75 |
| Forward PE | 25.14 |
| Dividend | 1.45 (0.55%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 171,460 |
| Open | 265.30 |
| Previous Close | 264.40 |
| Day's Range | 263.90 - 271.00 |
| 52-Week Range | 153.65 - 289.50 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 288.84 (+6.58%) |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for UCB stock is "Buy." The 12-month stock price target is €288.84, which is an increase of 6.58% from the latest price.
News
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
United Community Banks Inc (UCB) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 65/100
United Community Banks Inc (UCB) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 65/100
Biogen And UCB Present Positive PHOENYCS GO Data For DZP In Treating Lupus
(RTTNews) - Biogen Inc. (BIIB), a biotechnology company, and UCB SA (UCB.BR), a biopharmaceutical company, on Thursday released clinical data from the PHOENYCS GO program, including Phase 3 PHOENYCS r...
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Psoriatic Arthritis Trial
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...